KYMR SEC Filings, Earnings & Splits

Kymera Therapeutics announced its financial results for the quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1 to this Form 8-K.

Kymera Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing routine financial results, collaboration agreements with Sanofi and Gilead, and equity compensation details.

A Schedule 13G/A amendment was filed regarding beneficial ownership of Kymera Therapeutics (KYMR) common stock. The filing indicates a change in a holder's ownership position, though specific details are not disclosed in the available text.

An institutional investor filed an amended Schedule 13G indicating a change in its passive ownership position in Kymera Therapeutics. The filing does not disclose a specific ownership percentage or share count in the available text.

An institutional holder filed an amended Schedule 13G for Kymera Therapeutics, indicating a change in passive ownership position. The filing does not disclose a specific corporate event.

An institutional holder filed an amended Schedule 13G for Kymera Therapeutics, indicating a change in passive ownership position. The filing text provided does not disclose specific ownership percentages or share counts.